Abstract:It is possible to repress amyloid precursor protein (APP) mRNA translation as a novel anti-amyloid pharmacotherapy for Alzheimer's Disease (AD). This therapeutic model is consistent with well-documented cases where AD pathology can be the genetic consequence of duplications of the APP gene. This genetic duplication caused increased brain APP dose leading to over-expression of Ab amyloid and then disease onset. These findings support our pharmacological goal to reduce APP expression. As due diligence, we showed that FDA drugs (i.e., paroxetine & N-acetyl cysteine) selectively reduced APP translation in neural and epithelial cells while maintaining compensatory APLP-1/-2 levels, but then these drugs also limited Aß production in vivo. Paroxetineis a well-known selective serotonin reuptake inhibitor (SSRI) and a clinical anti-depressant that was identified to inhibit APP 5'untranslated region (5'UTR)-luciferase reporter expression. We showed proof-of-concept that unlike other SSRIs, paroxetine exhibits a planar tricyclic aromatic benzodioxole structure and provided anti-amyloid activity in the brains of APP(Swe) transgenic mice. Additionally, posiphen, a + enantiomer of the well-tested anti-cholinesterase phenserine, passed phase I clinical trials for AD as an APP 5'UTR inhibitor. Encouraged by this, we screened the 110,000 compound molecular library at Harvard's Laboratory for Drug Discovery in Neurodegenerative Diseases that had been optimized to obtain pharmacologically favorable activity agents; for example small molecules that inhibit mesangial cell proliferation following three-dimensional pharmacophore modeling. From our screen, thirteen top leads shared chemical features pertinent to their potently blocking APP 5'UTR directed translation (IC-50: 1nM to ∼100nM). This correlated well with their selective suppression of APP expression in several neural cell lines. The top compounds of these APP 5'UTR inhibitors were 50-fold more potent blockers of Aß precursor translation than either paroxetineor posiphen. The most active lead was the ninth compound in the series, APP blocker-9 (“JTR-009”). Critically, JTR-009 effectively reduced APP levels in primary mouse E-18 cortical neurons at single nanomolar concentrations similar to that for the serum concentrations of effective clinical drugs. Our top APP translation blocker, JTR-009, is a planar tricyclic benzimidazole that could potentially intercalate into the single 146 base APP 5'UTR specific RNA stem loop. Confirming specificity, we are checking how JTR-009 blocks ribosome scanning of the APP 5'UTR to impede translation (Aß output) but not to interact with the 5'UTRs of APP-like protein (APLP-1/-2) mRNAs. We are currently determining the in vivo pharmacokinetics and tolerance of JTR-009, and we are completing a structure activity relationship (SAR) study of ten close analogs using primary cortical neurons from the B6-R1.40 genomic mouse model of AD.

Discovery and evaluation of novel SHIP-1 inhibitors

Regulation of inositol 5-phosphatase activity by the C2 domain of SHIP1 and SHIP2

SHIP1 modulation and proteome characterization of microglia

Alteration of gene expression and protein solubility of the PI 5-phosphatase SHIP2 are correlated with Alzheimer's disease pathology progression

Mechanisms controlling membrane recruitment and activation of autoinhibited SHIP1

Mechanisms controlling membrane recruitment and activation of the autoinhibited SHIP1 inositol 5-phosphatase

SHIP inhibition mediates select TREM2-induced microglial functions

INPP5D limits plaque formation and glial reactivity in the APP/PS1 mouse model of Alzheimer’s disease

Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease

Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells

Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as Multifunctional Agents for the therapy of Alzheimer's Disease.

Discovery of a novel SHP2 allosteric inhibitor using virtual screening, FMO calculation, and molecular dynamic simulation

Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer's disease in vitro and in vivo

Identification of novel brain penetrant GSK-3β inhibitors toward Alzheimer's disease therapy by virtual screening, molecular docking, dynamic simulation, and MMPBSA analysis

Novel Brain-Penetrant Inhibitor of G9a Methylase Blocks Alzheimer's Disease Proteopathology for Precision Medication.

Drugs targeting SHIP2 demonstrate potent antiproliferative effects irrespective of SHIP2 inhibition

Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease

Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors

P2‐497: Mechanism of Action of App Translation Blockers: from Model to Human

Discovery of 6-[(3 S,4 S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor

The Functional Roles of the Src Homology 2 Domain-Containing Inositol 5-Phosphatases SHIP1 and SHIP2 in the Pathogenesis of Human Diseases